STAT6-IN-1

• Description :

  STAT6-IN-1 (Compound 19a) is a STAT6 inhibitor with a high affinity for the SH2 domain of STAT6 (IC50=0.028 µM) . STAT6-IN-1 can be used in studies of allergic lung disease, allergic rhinitis, chronic obstructive pulmonary disease or cancer[1][2][3].

• UNSPSC :

  12352005

• Target :

  STAT

• Type :

  Reference compound

• Related Pathways :

  JAK/STAT Signaling; Stem Cell/Wnt

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cancer; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/stat6-in-1.html

• Purity :

  99.81

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C([C@H]1N(CCC1)C([C@H](C(C)(C)C)NC(/C=C(C2=CC=C(C=C2)OP(O)(O)=O)\C)=O)=O)N(C3=CC=CC=C3)C4=CC=C(C=C4)I

• Molecular Formula :

  C33H37IN3O7P

• Molecular Weight :

  745.54

• References & Citations :

  [1]Mandal PK, et al. Targeting the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 6 (STAT6) with Cell-Permeable, Phosphatase-Stable Phosphopeptide Mimics Potently Inhibits Tyr641 Phosphorylation and Transcriptional Activity. J Med Chem. 2015 Nov 25;58 (22) :8970-84. |[2]John S, et al. Stat6 inhibitors. Patent WO2014182928A2. |[3]Zhang F, et al. Ultrasound-triggered biomimetic ultrashort peptide nanofiber hydrogels promote bone regeneration by modulating macrophage and the osteogenic immune microenvironment. Bioact Mater. 2023 Aug 14;31:231-246.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1637532-68-3]